The ASX has queried Neurotech International (NTI) after its latest quarterly cash flow revealed less than two quarters of available funding.
In line with ASX listing rules, companies with less than six months of cash must explain whether current cash flows will continue, what steps are being taken to raise funds, and whether operations can continue.
Neurotech said it expected near-term cash flows to “remain broadly consistent” with current levels, reflecting ongoing R&D and operating costs.
It added that around $4.7 million is expected from a R&D tax incentive this quarter and confirmed it would continue operations on that basis.
The company is developing NTI164, a low-THC, broad-spectrum oral cannabinoid therapy being deeloped for paediatric neurological disorders like autism and recently launched an Authorised Prescriber (AP) program in Australia.
The company reported net cash used in operating activities of $A1.3m in the first quarter of FY26, down from $3.6m in the same period last year and $2.6m in Q4 FY25.
Western Sydney University endometriosis trial
Researchers at the NICM Health Research Institute at Western Sydney University are recruiting participants for a clinical trial investigating CBB for endometriosis-related gut symptoms.
The study will test whether an oral CBD isolate oil can help reduce pelvic pain and improve gastrointestinal issues such as bloating, nausea and vomiting in people diagnosed with endometriosis.
Eligible participants must be aged 18 or over, have a confirmed diagnosis via laparoscopy, MRI or ultrasound, live in Greater Western Sydney, and not have used cannabis in the past three months.